Trial · NCT07187674
The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
NCT07187674, Not applicable, Not yet recruiting, Harbin Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel. Trials, record NCT07187674. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07187674
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
- NCT number
- NCT07187674
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Harbin Medical University
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Interventions
- Iparomlimab and tuvonralimab combined with olaparib and paclitaxel
- First posted
- 2025-09-23
- Last updated
- 2025-09-23
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Pathological Complete Response (tpCR) | 5 months | No invasive cancer cells in breast and axilla（ypT0/is N0） |
| Secondary | Breast Pathological Complete Respons(bpCR) | 5 months | According to the evaluation method recommended by the international breast collaboration group：There is no residual invasive carcinoma in the primary breast lesion and regional lymph nodes, or only carcinoma in situ (such as ductal carcinoma in situ) remains. If there are solitary tumor cells or micrometastases in lymph nodes, it is still judged as non PCR。 |
| Secondary | Objective Response Rate(ORR) | 12 months | Objective response rates assessed according to RECIST 1.1 criteria |
| Secondary | 3-year Disease Free Survival | 40 months | The 3-year survival of Wu Bing evaluated according to RECIST 1.1 criteria |
| Secondary | Ratio of Residual Cancer Burden (RCB) 0-1 | 5 months | The RCB index is calculated by measuring indicators such as the size of the tumor bed, cell density, the proportion of in situ cancer, and lymph node metastasis |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | 40 months | |
| Other | Exploratory endpoint：PD-L1 expression level | 5 months | Judge according to CPS table |
| Other | Exploratory endpoint：TILs level | 5 months | The method used was to perform hematoxylin eosin (He) staining on tissue sections, and further distinguish them by the typical characteristics of different lymphocytes or immunohistochemistry (IHC) |
| Other | Exploratory endpoint：Ki-67 index | 40 months | Taking the proliferation index of 14% as the critical point, the larger the value, the higher the malignant degree |
| Other | Exploratory endpoint：Proportion of cd8+t cells | 5 months | Immunohistochemical staining and flow cytometry |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07187674
GET https://conductscience.org/api/trials/v1/NCT07187674/registered